About Eclosion Ventures
Eclosion Ventures is a venture capital firm founded in 2004. It is primarily based out of Geneva, Switzerland. As of Jan 2015, Eclosion Ventures has invested in 7 companies. It primarily invests in Seed round in Switzerland based startups. Its investments are spread across Life Sciences and Healthcare sectors. Most recently it participated in the $***** Post IPO round of Genkyotex Overall, Eclosion Ventures portfolio has seen 1 IPO and 2 acquisitions, namely Genkyotex and GeNeuro. A lot of funds co-invest with Eclosion Ventures, with names like Vesalius Biocapital Partners sharing a substantial percentage of its portfolio. Eclosion Ventures has team of 1 people including 1 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed & Series C
Portfolio IPOs
Portfolio Acquisitions
Eclosion Ventures' List of Top Investments
Eclosion Ventures has a portfolio of 7 companies. Their most notable investments include Genkyotex and GeNeuro.Their portfolio spans across Switzerland and France. They have invested in Life Sciences, Healthcare, across Seed, Series C stages. Here is the list of top investments by Eclosion Ventures:1. Genkyotex
Genkyotex develops small molecule therapeutics that selectively inhibit the NOX family of enzymes. This technology is targeted towards the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. The company’s lead product is GKT831, a dual inhibitor of NOX4 and NOX1, which is in clinical development for the treatment of scleroderma (chronic connective tissue) and NASH (liver disease).
Key facts about Genkyotex
- Founded Year: 2006
- Location: Geneva (Switzerland)
- Stage: Acquired
- Total Funding till date: $51.8M
- Employee Count: 3 as on Apr 30, 2026
- Investors: Societe Generale, Bpifrance and 13 Others
- Latest Funding Round: Post IPO, Aug 21, 2018, $*****
- Highlight: Acquired
2. GeNeuro
GeNeuro is a clinical stage company focussed on developing drugs for autoimmune diseases such as multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). It has developed GNbAC1, a humanized monoclonal antibody which neutralizes the MSRV-Env protein rather than targeting the patient's immune system. The candidate is currently in Phase IIb clinical development for MS. It is also planning to develop its platform for other neurological diseases and autoimmune diseases such as type 1 diabetes and chronic inflammatory demyelinating polyneuropathy.
Key facts about GeNeuro
- Founded Year: 2006
- Location: Plan les Ouates (Switzerland)
- Stage: Public
- Employee Count: 22 as on Jul 01, 2024
- Investors: Admin, Foundation Eclosion and 2 Others
- Latest Funding Round: Post IPO, Feb 02, 2024, $*****
- Highlight: Public
Developer of therapeutic solutions to treat cancer. The company is developing a pipeline of drugs targeting different ligands of dependence receptors. Its lead candidate is NP137 a monoclonal antibody that targets netrin-1, for the treatment of cancer.
Key facts about Netris pharma
- Founded Year: 2008
- Location: Lyon (France)
- Stage: Series A
- Total Funding till date: $8.21M
- Employee Count: 1 as on Apr 30, 2026
- Investors: Foundation Eclosion, Wille Finance and 2 Others
- Latest Funding Round: Series A, Dec 20, 2023, $*****
- Highlight: Editors' Pick
Chord Therapeutics is a developer of drugs for the treatment of rare neurological diseases. It aims to redevelop CRD1, to bring new therapies for severe, rare autoimmune neurological diseases. The company is repurposing the small molecule drug CRD1, under orphan drug/orphan medicinal product designation for the treatment of Neuromyelitis optica (NMO), also known as Devic's disease or Devic's syndrome. Currently, no treatment for neuromyelitis Optica (NMO) has been granted regulatory approval, and no controlled clinical studies have been reported.
Key facts about Chord Therapeutics
- Founded Year: 2014
- Location: Plan les Ouates (Switzerland)
- Stage: Acqui-Hired
- Total Funding till date: $16M
- Employee Count: 1 as on Jul 01, 2024
- Investors: Foundation Eclosion, Omega Funds and 1 Other
- Latest Funding Round: Series A, Oct 13, 2020, $*****
- Highlight: Editors' Pick
5. Epithelix
Epithelix is a tissue engineering company providing in-vitro solutions for drug development and toxicity testing for the human respiratory tract. Epithelix provides R&D solutions to Pharma/Biotechs for the study of human respiratory diseases (asthma, COPD, cystic fibrosis, etc.) in order to reduce animal experiments. Its main product, MucilAir, is a 3-D model of the human airway epithelium made up of primary human cells isolated from the nasal cavity, trachea, and bronchus.
Key facts about Epithelix
- Founded Year: 2006
- Location: Plan les Ouates (Switzerland)
- Stage: Seed
- Employee Count: 19 as on Apr 30, 2026
- Investors: Foundation Eclosion, Europa and 1 Other
- Latest Funding Round: Grant (prize money), Jan 01, 2020, $*****
Eclosion Ventures' Investments by Stage
Eclosion Ventures has made 2 investments in Seed stage and 1 investment in Series C stage with an average round size of $20.4M.Stage of entry | No. of Investments |
|---|---|
Seed | 2 |
Series C | 1 |
Note: We have considered here, only first round of investments
Eclosion Ventures' Investments by Sector
Eclosion Ventures has a diverse portfolio, with companies operating in the Healthcare and Life Sciences. Notably, it has invested in 5 Enterprise (B2B) companies, 5 Tech companies, 1 Consumer (B2C) company and at least 1 company focusing on Social impact.Sector | No. of Investments |
|---|---|
Healthcare | 2 |
Life Sciences | 2 |
Note: We have considered here, only first round of investments
Eclosion Ventures' Investments by Geography
Eclosion Ventures has made most investments in Switzerland (3).Eclosion Ventures' recent investments
Eclosion Ventures has not made any investment in 2026 so far.Here are the most recent investments by Eclosion Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 07, 2015 | Switzerland | Post IPO | 8291 | [+4] | |
2014 | Switzerland | Seed | 6764 | - | |
Feb 2014 | Switzerland | Seed | 2305 | - | |
Jul 09, 2012 | Switzerland | Series C | 5702 | ||
May 24, 2011 | Switzerland | Series C | 4071 |
IPOs and Publicly Listed companies in Eclosion Ventures' Portfolio
1 of Eclosion Ventures' portfolio company became public - GeNeuro. It got listed on the Euronext Exchange (Euronext), in Apr 2016 at marketcap of $204MHere are Eclosion Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 15, 2016 | - | - | 2086 |
Acquired companies in Eclosion Ventures' Portfolio
2 companies from Eclosion Ventures' portfolio have been acquired. The most recent acquisition was Chord Therapeutics in Dec 2021 by Merck for $*****.Here are Eclosion Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 20, 2021 | Feb 2014 | Seed | 7644 | |
Aug 13, 2020 | May 24, 2011 | Series C | 8677 |
Team profile of Eclosion Ventures
Eclosion Ventures has a team of 1 member located in Switzerland. Eclosion Ventures' team does not sit on the board of any company as of now.Co-investors of Eclosion Ventures
Over the past 15 years, 9 investors have co-invested in Eclosion Ventures's portfolio companies. This includes only funds.
- Invested before Eclosion Ventures: Societe Generale and Eclosion have invested in rounds before Eclosion Ventures. There is 1 company where Societe Generale has invested before Eclosion Ventures and 1 company where Eclosion has invested before Eclosion Ventures.
- Top Co-investors of Eclosion Ventures: 3 investors entered a company along with Eclosion Ventures. These include investors like Vesalius Biocapital Partners (1 company).
- Invested after Eclosion Ventures: A total of 4 investors have invested in Eclosion Ventures's portfolio after their investments. Top Investors include NeoMed (1 company), VI Partners (1 company) and BioMedPartners (1 company).
